信达生物-B(01801.HK)中期收入达3.455亿元 研发开支增至6.707亿元
格隆汇8月29日丨信达生物-B(01801.HK)8月28日晚间公布截至2019年6月30日止6个月的中期业绩，集团实现总收入(包括集团于2019年3月9日开始销售首个商业化药物产品达伯舒(信迪利单抗注射液)产生的销售额3.316亿元)为3.455亿元人民币(单位下同)，去年同期的总收入则为人民币440万元。达伯舒(信迪利单抗注射液)的成功上市推动集团进入业务周期的商业化阶段，并充分发挥多功能全面集成平台的潜力，在各大治疗领域探索、开发、生产及销售创新药物。
截至2019年6月30日止6个月的毛利率为88.1%，反映公司于商业化生产初期即具备生产质量稳定的达伯舒(信迪利单抗注射液)的能力。
截至2019年6月30日止6个月的研发开支增加2.507亿元至6.707亿元，去年同期则为4.200亿元。有关增加乃主要由于(i)因向中国国家药品监督管理局(“NMPA”)提交新药临床试验(“IND”)而根据与Incyte Biosciences International Sàrl(“Incyte”)(Incyte Corporation(NASDAQ:INCY)的附属公司)订立的合作及许可协议向其支付阶段付款1.644亿元，及(ii)集团的更多候选药物于2019年上半年进入后期临床开发，令临床试验开支增加所致。
截至2019年6月30日止6个月的销售及市场推广开支增加2.695亿元至2.796亿元，去年同期则为1010万元。有关增加乃主要由于达伯舒(信迪利单抗注射液)于2019年上半年成功上市所致。
截至2019年6月30日止6个月的亏损及全面开支总额增加6.568亿元至7.144亿元，去年同期则为5760万元。有关增加乃主要由于(i)去年同期根据国际财务报告准则的要求确认优先股公允价值收益的一次性非现金调整4.488亿元，及(ii)经调整亏损及全面开支总额增加2.032亿元，乃主要由于研发开支及销售及市场推广开支增加所致，部分由达伯舒(信迪利单抗注射液)的销售额所抵销。
值得注意的是，去除以股份为基础的酬金开支及若干非现金项目及一次性事件的影响，即优先股(按公允价值计量且其变动计入损益的其他金融负债)公允价值变动，期内经调整亏损及全面开支总额为6.676亿元，而去年同期则为4.644亿元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
